Last reviewed · How we verify

Ibuprofen/famotidine — Competitive Intelligence Brief

Ibuprofen/famotidine (Ibuprofen/famotidine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID with gastroprotective agent. Area: Pain management / Gastroenterology.

phase 3 NSAID with gastroprotective agent COX-1/COX-2 (ibuprofen); H2 histamine receptor (famotidine) Pain management / Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Ibuprofen/famotidine (Ibuprofen/famotidine) — Amgen. This combination drug reduces stomach acid (via famotidine, an H2-receptor antagonist) while providing anti-inflammatory and analgesic effects (via ibuprofen, an NSAID), designed to minimize gastrointestinal injury from NSAID use.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ibuprofen/famotidine TARGET Ibuprofen/famotidine Amgen phase 3 NSAID with gastroprotective agent COX-1/COX-2 (ibuprofen); H2 histamine receptor (famotidine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID with gastroprotective agent class)

  1. Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ibuprofen/famotidine — Competitive Intelligence Brief. https://druglandscape.com/ci/ibuprofen-famotidine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: